Phrma company information, Employees & Contact Information

Medicare Monday: How to switch plans during open enrollment PhRMA

PBMs, not patents, are blocking access to lower-cost medicines PhRMA

PBMs say they want lower priced medicines, so why don’t they cover them? PhRMA

Michigan proposal jeopardizes access to medicines PhRMA

Part D premiums are going up, while choices are going down PhRMA

New study: PBMs and commercial insurers are quietly blocking prescription access PhRMA

The hidden cost of 340B: A multi-billion-dollar burden on taxpayers and Medicaid PhRMA

PBMs are hiding hurdles to essential care PhRMA

Ensuring access to affordable medicines for patients through Medicaid PhRMA

Fact Check Friday: The truth about Industry’s role in R&D PhRMA

New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines PhRMA

Curbing 340B abuse and rising costs with the rebate model PhRMA

PBMs & Middlemen PhRMA

Cost & Value of Medicines PhRMA

Delivering breakthroughs and lower costs for patients PhRMA

Tariffs on medicines would harm American competitiveness, industry and patients PhRMA

Medical innovation takes center stage in state legislatures PhRMA

New report finds rampant abuse of the 340B program PhRMA

Study: 340B hospitals drive up patient drug costs PhRMA

Bringing to life the full story of biopharmaceutical innovation and investments PhRMA

New report: How intellectual property drives U.S. innovation and biopharma's impact PhRMA

Americans are paying a 26% freerider tax on medicines because other countries don’t pay their fair share PhRMA

The tradeoffs: Personalized treatment vs. one-size-fits-all standards PhRMA

ICYMI: The Wall Street Journal calls 340B reform a “good idea to cut drug costs” PhRMA

PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021 PhRMA

Strong Trade Policies Protect American Workers and Biopharmaceutical Innovation PhRMA

PhRMA stresses importance of 340B Rebate Model Pilot PhRMA

Government price-setting boards: Why Minnesota needs to take a better approach PhRMA

Foreign first pricing schemes don’t address why Americans pay more PhRMA

How the 340B hospital markup program and PBMs drive up costs for U.S. patients PhRMA

Celebrating 60 Years of Medicare PhRMA

New “Meet Mark” ad exposes how the 340B hospital markup program drives up costs for everyone PhRMA

Answering common questions on mRNA technology PhRMA

USTR 2025 Special 301 Report corrects course PhRMA

CBO: 340B program costs taxpayers, no evidence patients benefit PhRMA

The AHIP premium dollar corrected (again) PhRMA

Medicare patients face higher drug costs, despite IRA promises PhRMA

4 key facts on medicine prices and spending PhRMA

New analysis: Fewer treatments and cures under the IRA’s pill penalty PhRMA

When hospitals have free rein to mark up drug prices, who pays the price? PhRMA

How the IRA is impacting the generic drug market PhRMA

ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development PhRMA

4 things to know on Rare Disease Day PhRMA

New poll shows strong bipartisan support for PBM reform PhRMA

New study: Entities that don’t make medicines get half of what is spent on those medicines PhRMA

ICYMI: PhRMA President and CEO Stephen J. Ubl discusses patient affordability PhRMA

Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change PhRMA

The biopharmaceutical industry is one of the highest contributors to America’s economy among all manufacturers PhRMA

A successful PhRMA Forum highlights our commitment to a healthier America PhRMA

Congress Keeps PBMs in the Hot Seat PhRMA

What to know about vaccine ingredients: Aluminum and thimerosal PhRMA

Report: The Pharmaceutical Supply Chain, 2013-2023 PhRMA

WTAS: Proposed Unsubstantiated USPTO Rule Change is a Threat to American Innovation PhRMA

New report sheds light on payment flows in the pharmaceutical supply chain, including the role of 340B and vertical integration PhRMA

Medicare Monday: What Part D Extra Help means to patients like Diane PhRMA

Patient safety is at the heart of COVID-19 vaccine R&D PhRMA

Biopharmaceutical innovation for a healthier America: PhRMA releases new innovation report PhRMA

New research: Industry sponsored clinical trials contribute billions to state economies PhRMA

What is missing in the current drug pricing plan PhRMA

PhRMA CEOs Tee Up Next Week's Health Care Conference PhRMA

FTC finds PBMs make billions in profit from marking up cancer, other critical generic drugs PhRMA

Major drug compounder is spending millions on misleading Super Bowl ad PhRMA

Medicare Monday: Billing code basics for biologics in Part B PhRMA

NYT exposes hospitals, middlemen make millions off a hospital markup program PhRMA

New 340B report from Minnesota exposes steep hospital markups on medicines, patient benefits remain unclear PhRMA

The PBM industry's desperate attempt to stop reform PhRMA

Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult. PhRMA

WTAS: Inflation Reduction Act already impacting R&D decisions PhRMA

How government price setting fails to address systemic health care inequities PhRMA

Three ways state drug price setting boards fail patients PhRMA

Intellectual Property PhRMA

The use of real-world data in drug development PhRMA

How 340B discounts work PhRMA

New analysis shows PBMs use fees as a profit center PhRMA

Hospitals and 340B PhRMA

Global Access to New Medicines Report PhRMA

New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election PhRMA

New global analysis shows patient access challenges around the world PhRMA

Patients need to pay less for their medicines. States can help. PhRMA

Biopharmaceutical industry supports jobs and drives economic growth across the United States PhRMA

PBMs using 340B program to drive profits at patients’ expense PhRMA

Insurance data: PBM reform has no material impact on premiums PhRMA

The truth about Nebraska's price setting push PhRMA

New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines PhRMA

Where voters stand ahead of the election PhRMA

More oversight needed of unapproved medicines that threaten patients’ health PhRMA

New 50-state poll Americans want to hold health insurers and PBMs accountable for high out-of-pocket costs and other practices PhRMA

An open letter to Congress: Stand with patients and future cures PhRMA

Don't close the door on rare disease research PhRMA

A Sustained Commitment to Advancing Diversity, Equity, and Inclusion PhRMA

New research: American biopharmaceutical investment in R&D drives transformational innovation PhRMA

IRA threatens seniors’ access to robust treatment options PhRMA

Government Price-Setting Policies Do Not Address Systemic Health Equity Issues PhRMA

The IRA’s pill penalty threatens the future of oncology R&D PhRMA

New Report: Vaccines continue to drive improved health outcomes PhRMA

Recent events highlight progress on health equity PhRMA

Identifying and addressing health disparities: PhRMA's first chart pack on health equity PhRMA

Inflation Reduction Act Already Impacting R&D PhRMA

PhRMA submission calls for USTR to correct course on trade policy, enforcement PhRMA

How HTA-based price controls could worsen health outcomes and health disparities PhRMA